Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Capital Expenditures (2021 - 2025)

Biofrontera has reported Capital Expenditures over the past 5 years, most recently at -$1000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at -$1000.0 for Q4 2025, up 97.5% from a year ago — trailing twelve months through Dec 2025 was $2000.0 (down 80.0% YoY), and the annual figure for FY2025 was $2000.0, down 80.0%.
  • Capital Expenditures for Q4 2025 was -$1000.0 at Biofrontera, roughly flat from -$1000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for BFRIW hit a ceiling of $57000.0 in Q1 2024 and a floor of -$40000.0 in Q4 2024.
  • Median Capital Expenditures over the past 5 years was $1000.0 (2022), compared with a mean of $4200.0.
  • Biggest five-year swings in Capital Expenditures: plummeted 1000.0% in 2023 and later surged 307.14% in 2024.
  • Biofrontera's Capital Expenditures stood at $9000.0 in 2021, then plummeted by 88.89% to $1000.0 in 2022, then plummeted by 1000.0% to -$9000.0 in 2023, then crashed by 344.44% to -$40000.0 in 2024, then skyrocketed by 97.5% to -$1000.0 in 2025.
  • The last three reported values for Capital Expenditures were -$1000.0 (Q4 2025), -$1000.0 (Q3 2025), and $1000.0 (Q2 2025) per Business Quant data.